Tina Mickle
Family · Prescott Valley, AZNPI 1215450374
Payments from drug & device makers
Across 121 payments — averaging $17.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$229
- Novo Nordisk$223
- Pfizer$190
- Sanofi-aventis U.S. LLC$180
- GSK$158
- AbbVie$157
- plus $991 from 23 others
What the payments were for
- Food & beverage$2,128100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 16 | $229 |
| Novo Nordisk | 12 | $223 |
| Pfizer | 11 | $190 |
| Sanofi-aventis U.S. LLC | 12 | $180 |
| GSK | 9 | $158 |
| AbbVie | 7 | $157 |
| Lilly USA, LLC | 6 | $104 |
| Indivior Inc. | 4 | $103 |
| Medtronic | 6 | $91 |
| Mylan Specialty L.p. | 5 | $91 |
| AstraZeneca | 6 | $88 |
| Nestle Healthcare Nutrition Inc. | 4 | $74 |
| Biohaven Pharmaceuticals, Inc. | 3 | $53 |
| Aimmune Therapeutics, Inc. | 2 | $50 |
| Abbott | 2 | $45 |
| Exact Sciences | 2 | $35 |
| Phadia US Inc. | 2 | $32 |
| Edwards Lifesciences | 1 | $29 |
| Viiv Healthcare Company | 1 | $23 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Astellas Pharma US Inc | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Eisai Inc. | 1 | $20 |
| Bardy Diagnostics, Inc. | 1 | $19 |
| Bayer | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Boehringer Ingelheim | 1 | $14 |
| Advanced Oxygen Therapy Inc. | 1 | $12 |
How this compares
$2,128 in reported general payments places this provider in the 80th percentile of 4,119 family providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 68 | $83,193 |
| OzempicSemaglutide | 55 | $51,527 |
| JardianceEmpagliflozin | 25 | $28,012 |
| FarxigaDapagliflozin Propanediol | 17 | $19,881 |
| JanuviaSitagliptin Phosphate | 14 | $19,777 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $16,814 |
| TrulicityDulaglutide | 12 | $13,141 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $12,489 |
| LinzessLinaclotide | 11 | $8,903 |
| SymbicortBudesonide/Formoterol Fumarate | 23 | $7,077 |
| Advair HfaFluticasone Propion/Salmeterol | 14 | $6,496 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 152 | $4,347 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 16 | $3,230 |
| Gabapentin | 155 | $2,798 |
| Levothyroxine Sodium | 318 | $2,727 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $190 | $83,19368 claims |
| Novo NordiskOzempic | $223 | $51,52755 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $88 | $39,44752 claims |
| Boehringer IngelheimJardiance | $14 | $28,01225 claims |
| GSKTrelegy Ellipta | $158 | $16,81417 claims |
| Lilly USA, LLCTrulicity | $104 | $13,14112 claims |
| AbbVieLinzess, Synthroid | $157 | $10,38541 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,119 family providers in Arizona.
Other family in Prescott Valley
- Sharon MagalonaMesa$449K
- Angela GoldenMunds Park$378K
- Kimberly HallaPhoenix$332K
- Kaitlyn LouchheimScottsdale$208K
- Rebecca McCollaumMesa$149K
- Susan SarabiaSun City West$114K
- Lindsay CarterTucson$108K
- Audrey StevensonPhoenix$83K
- Keith MorsePrescott$83K
- Celeste FineGilbert$82K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.